C.R. Bard Inc. (NYSE:BCR) – KeyCorp boosted their FY2017 earnings estimates for shares of C.R. Bard in a report released on Tuesday. KeyCorp analyst M. Mishan now expects that the brokerage will earn $11.34 per share for the year, up from their prior estimate of $11.30.
C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Tuesday, July 26th. The company reported $2.54 earnings per share for the quarter, topping analysts’ consensus estimates of $2.47 by $0.07. The company had revenue of $931.50 million for the quarter, compared to analyst estimates of $915.22 million. During the same quarter in the previous year, the company posted $2.27 earnings per share. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year.
Several other equities analysts have also weighed in on BCR. Leerink Swann raised their target price on C.R. Bard from $196.00 to $205.00 and gave the company a “market perform” rating in a report on Wednesday, March 30th. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $227.00 price target on the stock in a research report on Wednesday, March 30th. Barclays PLC raised their price target on C.R. Bard from $195.00 to $212.00 and gave the company an “equal weight” rating in a research report on Thursday, April 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research report on Thursday, April 28th. Finally, Morgan Stanley reaffirmed a “hold” rating on shares of C.R. Bard in a research report on Sunday, May 22nd. Thirteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. C.R. Bard presently has a consensus rating of “Hold” and a consensus price target of $232.85.
In other news, insider John P. Groetelaars sold 1,162 shares of C.R. Bard stock in a transaction that occurred on Tuesday, May 17th. The shares were sold at an average price of $219.88, for a total value of $255,500.56. Following the completion of the transaction, the insider now owns 17,431 shares in the company, valued at $3,832,728.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Christopher S. Holland sold 3,970 shares of C.R. Bard stock in a transaction that occurred on Friday, May 27th. The shares were sold at an average price of $219.89, for a total transaction of $872,963.30. Following the completion of the transaction, the chief financial officer now owns 31,306 shares of the company’s stock, valued at approximately $6,883,876.34. The disclosure for this sale can be found here.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 29th. Shareholders of record on Monday, July 18th will be issued a dividend of $0.26 per share. This is an increase from C.R. Bard’s previous quarterly dividend of $0.24. This represents a $1.04 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date of this dividend is Thursday, July 14th.
C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.
